Material Event (Form 8-K)

Item 8.01 Other Events.

As previously disclosed, on February 25, 2026, PDS Biotechnology Corporation (the "Company") received a deficiency letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

On June 2, 2026, the Company received written notice from Nasdaq informing the Company that it has regained compliance with the Minimum Bid Price Requirement and that Nasdaq has closed the matter.